CTLA4 and melanoma: A decade ago, stage IV melanoma was a death sentence, whereas today, up to half of all stage IV melanoma patients can expect to be cured of their disease through combination anti-CTLA-4 (ipilimumab)/anti-PD-1 (nivolumab or pembrolizumab) checkpoint inhibition (Table 1) (81–83).